Retatrutide price, Phase 3 results, trials, and FDA status.
Also searched as LY3437943 · triple agonist · reta · reta peptide
Retatrutide is Lilly’s investigational once-weekly triple receptor agonist for chronic weight management and related conditions. Phase 3 topline results now exist, but the most-cited percentages come from different TRIUMPH populations, durations, doses, and statistical estimands - not a head-to-head ranking against approved medicines.
Is Retatrutide FDA approved or available?
No. Lilly's Phase 3 reporting does not make Retatrutide an approved medicine. As of July 21, 2026, there is no FDA-approved product, commercial dose, pharmacy price, or routine prescription channel. Same-name research listings cannot inherit the identity or evidence of Lilly's clinical program.
Compare Retatrutide with CagriSema, without losing the country context.
Put evidence status, ClinicalTrials.gov coverage, official United States records, and qualified US research prices in one view. Blank fields stay blank when the underlying dataset does not support a number.
Investigational clinical program
Official product and seller records attached
Investigational clinical program
What can you conclude about Retatrutide today?
These are dated program facts, not a cross-trial ranking, approval forecast, personal treatment recommendation, or proof that a same-name online product is the sponsor's medicine.
A single investigational molecule designed to activate GIP, GLP-1, and glucagon receptors.
Average loss at 12 mg in Lilly’s efficacy-estimand topline analysis among adults without diabetes.
Reported for the 12 mg TRIUMPH-1 group under the efficacy estimand; not a guaranteed individual result.
TRIUMPH studies span obesity, type 2 diabetes, knee osteoarthritis, and other complications.
Know which molecule the result belongs to.
- Sponsor
- Eli Lilly and Company
- Mechanism
- GIP + GLP-1 + glucagon receptor agonist
- Route being studied
- Once-weekly subcutaneous injection
- Current stage
- Phase 3 program reporting results
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
- Evidence checked
- July 20, 2026
Retatrutide weight-loss results, with the trial attached.
This visual shows one selected result, not every dose or endpoint in the program. The percentage remains attached to its duration, population, comparator, analysis method, and source.
Evidence checked July 21, 2026Retatrutide reported 28.3% mean reduction at 80 weeks under the efficacy estimand. The comparator recorded 2.2% mean reduction.
Bar lengths share a 0 to 30% visual scale. They describe this selected record and do not make separate trials head-to-head.
- Population
- Adults with obesity or overweight and at least one complication
- Participants
- 2,339 Total randomized master-trial population
- Dose
- 12 mg
- Primary analysis
- Efficacy estimand
- Alternate analysis
- Treatment-regimen estimand
- Regulatory status
- Investigational; not FDA approved
Retatrutide clinical trials by status, phase, and location.
The current exact-intervention snapshot matches 34 unique NCT records. This chart describes registry coverage and current study fields. It does not compare efficacy, safety, approval probability, eligibility, or treatment access.
Snapshot 2026-07-24Counts use individual locations currently marked Recruiting, not every facility listed on an overall-recruiting study. Repeated centers across studies remain repeated site observations.
Which Retatrutide studies are actually recruiting?
Check 2 overall-recruiting records, 11 active studies that are no longer recruiting, 27 recruiting-site countries, 34 US states, exact condition requirements, and the separate expanded-access pathway using a dated ClinicalTrials.gov snapshot.
Open the Retatrutide clinical-trial tracker →Do public Retatrutide COAs establish Lilly program identity?
No. The public ledger preserves 27 same-name seller report routes while keeping them separate from Lilly's investigational material, manufacturing controls, clinical evidence, and legal status.
Inspect the public Retatrutide report trail →Retatrutide across 42 countries.
This profile establishes the program identity and its cited clinical or regulatory record. It does not turn a same-name seller listing into the sponsor’s asset or prove authorization, availability, or lawful supply in another destination.
Compare Retatrutide by country →Compare Retatrutide by US state →Browse the global peptide country dataset →Is Retatrutide approved or available in your country?
Start with the United States FDA record, then check the destination that matters to you. Each country page separates drug identity, authorization, product records, seller claims, and supply rules. Directory checked July 20, 2026.
What the record shows - and what it doesn’t.
Trial percentages are kept beside the design details that make them interpretable. Unknowns stay visible instead of being filled with launch speculation.
TRIUMPH-1 provides a large Phase 3 record
Lilly reported that adults with obesity or overweight without diabetes receiving 12 mg retatrutide lost an average 28.3% at 80 weeks under the efficacy estimand, versus 2.2% with placebo. The 4 mg group lost 19.0%. The sponsor reports 2,339 randomized participants and ClinicalTrials.gov lists a completed study record.
The 30% figure is a responder threshold
In the 12 mg TRIUMPH-1 group, 45.3% of participants achieved at least 30% weight loss under the efficacy estimand. That percentage describes the proportion crossing a threshold in one randomized trial arm; it is not the group’s average loss, an approved-label promise, or evidence that every participant responds similarly.
A second Phase 3 population has reported
TRIUMPH-4 studied adults with obesity or overweight and knee osteoarthritis. Lilly reported up to 28.7% average loss at 68 weeks under an efficacy estimand alongside improvement in osteoarthritis pain. The population, duration, and clinical question differ from TRIUMPH-1, so the two maxima should not be blended.
No FDA approval or commercial label
Retatrutide does not have an FDA-approved indication, dose-escalation schedule, retail price, insurance policy, or legitimate pharmacy launch. A Phase 3 result and a completed trial record are milestones, not marketing authorization.
No valid ‘strongest drug’ conclusion
The reported percentages cannot establish that retatrutide is stronger than another medicine without an appropriate head-to-head randomized trial. Population, adherence assumptions, trial duration, dose, missing-data handling, and comparator all influence cross-trial numbers.
Long-term benefit-risk is still developing
Additional TRIUMPH results, detailed publications, regulatory review, and longer follow-up are still needed to characterize durability, discontinuation effects, uncommon adverse events, cardiovascular outcomes, and the benefit-risk profile of the glucagon component.
The questions behind the search.
Concise answers based on the dated sponsor and trial records below. This is educational reporting, not medical advice.
What is retatrutide and how does it work?
Retatrutide, also known as LY3437943, is Lilly’s investigational once-weekly molecule designed to activate three receptors: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. That is why it is commonly called a triple agonist. The mechanism is being studied for chronic weight management and related metabolic conditions, but it remains a clinical-stage drug. The receptor description is not an approved indication, dosing instruction, or reason to buy products using the name online.
How much weight loss did retatrutide produce in Phase 3?
In Lilly’s TRIUMPH-1 topline release, the 12 mg group had 28.3% average weight loss at 80 weeks under the efficacy estimand, which estimates the effect if participants adhered to treatment, compared with 2.2% for placebo. The 4 mg group had 19.0%. Lilly also reported that 45.3% of participants in the 12 mg group crossed the 30% loss threshold. These are group-level trial estimates in adults without diabetes, not predictions for an individual and not a direct comparison with another drug.
Is retatrutide approved or available now?
No. Retatrutide is still investigational as of this evidence check, even though multiple Phase 3 trials have reported or completed. There is no FDA-approved retatrutide product, label, commercial dose, pharmacy price, or routine prescription channel. Online research-vial listings do not convert an investigational development name into an approved medicine, and their identity should not be inferred from the sponsor’s clinical evidence. Regulatory submission and review are separate future steps unless Lilly or a regulator documents them.
Can you buy retatrutide in the United States?
There is no FDA-approved retatrutide medicine to buy from a US pharmacy. Lilly states that retatrutide is legally available only to participants in its clinical trials. Websites may sell research vials using the same name, but those listings are not Lilly’s clinical-trial material, do not create an approved retail channel, and cannot borrow identity, quality, dose, or safety evidence from the TRIUMPH program. The legitimate access question is therefore trial eligibility, not which online seller uses the name.
What is the price or cost of retatrutide?
Retatrutide has no official US retail price because it is not an approved or commercially launched medicine. There is no manufacturer list price, standard pharmacy cash price, insurance formulary price, or approved monthly treatment cost. Prices attached to online research vials describe separate seller listings and should not be presented as the price of Lilly’s investigational drug. If retatrutide is submitted, approved, and launched, manufacturer and pharmacy records will be needed before a legitimate cost comparison exists.
What side effects were reported in the TRIUMPH-1 Phase 3 trial?
Lilly reported that gastrointestinal events were most common and generally mild to moderate. At 12 mg, nausea occurred in 42.4% of participants, diarrhea in 32.0%, constipation in 26.1%, and vomiting in 25.3%, compared with 14.8%, 13.5%, 10.9%, and 4.8% on placebo. Dysesthesia was reported in 12.5% at 12 mg versus 0.9% on placebo, and 11.3% in the 12 mg group discontinued because of adverse events versus 4.9% on placebo. These sponsor topline data are not a complete prescribing safety profile.
Where can I find official retatrutide clinical trials?
Use ClinicalTrials.gov records sponsored by Eli Lilly and Company, then verify the recruiting status and contact details on the exact study record. TRIUMPH-1 is NCT05929066 and TRIUMPH-4 is NCT05931367. A completed trial can explain results but cannot enroll new participants. Trial registries, not seller pages or social-media posts, are the appropriate source for locations, eligibility criteria, enrollment status, and official study contacts.
Is retatrutide better than semaglutide?
No head-to-head randomized trial cited here establishes that retatrutide is better than semaglutide. Retatrutide’s TRIUMPH-1 and semaglutide’s STEP program used different populations, durations, doses, adherence assumptions, missing-data methods, and comparators. Headline percentages can describe each trial, but ranking the drugs from separate studies overstates the evidence. The dedicated comparison keeps status, design, results, adverse-event context, and evidence limits side by side.
Do not use an investigational name, trial dose, or online research listing as a substitute for approved care. This page does not recommend treatment, sourcing, or participation in a clinical trial.
Understand the product-category boundary →